BMY and JNJ Financials: 2025 Revenue Numbers Declared
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowFor FY 2025, Bristol Myers Squibb (BMY) reported revenue of approximately $48.2 billion, reflecting a slight decline of 0.2% year-over-year, while net income was $7.1 billion, yielding a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved revenue of about $94.2 billion, marking a 6.0% increase, with a net income of nearly $26.8 billion and a net margin of 28.5%. BMY's debt-to-equity ratio stood at 2.6x, while JNJ's was 0.6x, indicating differing financial leverage. Their performance could influence investor strategies given the contrasting growth potential and stability they provide.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb is a major pharmaceutical company focused on oncology and immunology.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BMY news
- SCHD Fund Achieves 20% Return with $71.6B Assets and 3.3% Yield
- Bristol Myers (BMY) Uses Claude AI for Drug Discovery Initiative
- Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
- Bristol-Myers Squibb (BMY) Offers Low Volatility and High Yield
- BMY Stock Rating Reiterated at Buy by Guggenheim
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
